SCHEMBL2750474

SCHEMBL2750474

CCCC1CC(=O)N(Cn2c(Cl)nc3cc([N+](=O)[O-])ccc32)C1

nearest known ligand 0.39

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 1/20 0.39
MAPT P10636 1/20 0.39
KMT2A Q03164 5/20 0.38
OPRM1 P35372 2/20 0.38
MEN1 O00255 3/20 0.37
ALDH1A1 P00352 2/20 0.37
PKM P14618 1/20 0.37
CYP1A2 P05177 1/20 0.37
CFTR P13569 4/20 0.37
ALOX5 P09917 1/20 0.36
ALOX15 P16050 1/20 0.36
PTGS2 P35354 1/20 0.36
LMNA P02545 1/20 0.36
CYP2D6 P10635 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2333631 0.92 CYP1A2 (0.37) MAPTKMT2AMEN1ALDH1A1CYP1A2
SCHEMBL1668835 0.86 KMT2A (0.37) KMT2AALDH1A1
SCHEMBL2331161 0.85 PPARG (0.34) CNR2CFTR
SCHEMBL12000450 0.85 P2RX3 (0.38) CNR2ALDH1A1
SCHEMBL1665515 0.82 TDP1 (0.42) MAPTKMT2AALDH1A1CYP1A2
SCHEMBL5060899 0.82 CNR2 (0.42) CNR2ALDH1A1
SCHEMBL2750491 0.81 MEN1 (0.34) KMT2AMEN1LMNA
SCHEMBL1665637 0.81 LMNA (0.42) MAPTALDH1A1LMNA
SCHEMBL2332123 0.80 ACSS2 (0.34) LMNA
SCHEMBL2748577 0.80 ALOX5 (0.35) ALOX5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8178533-B2 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses UCB PHARMA, S.A. (BE) 2012-05-15 US claimed
EP-1912966-A2 2-OXO-1-PYRROLIDINE DERIVATIVES AND THEIR THERAPEUTIC USE ON THE CENTRAL NERVOUS SYSTEM UCB, S.A. (BE) 2008-04-23 EP claimed
EP-1891042-A2 2-OXO-1-PYRROLIDINE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR THERAPEUTIC USE ON THE CENTRAL NERVOUS SYSTEM UCB Pharma, S.A. (BE) 2008-02-27 EP claimed
WO-2006128693-A2 2 -OXO-I -PYRROLIDINE DERIVATIVES/ PROCESSES FOR PREPARING THEM AND THEIR THERAPEUTIC USE ON THE CENTRAL NERVOUS SYSTEM UCB PHARMA, S.A. (BE) 2006-12-07 WO claimed
WO-2006128692-A2 2-OXO-1-PYRROLIDINE DERIVATIVES AND THEIR THERAPEUTIC USE ON THE CENTRAL NERVOUS SYSTEM UCB PHARMA, S.A. (BE) 2006-12-07 WO claimed
EP-2533645-B1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION UNIV JOHNS HOPKINS (US) 2016-07-27 EP disclosed
EP-2968237-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION The Johns Hopkins University (US) 2016-01-20 EP disclosed
EP-2968220-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION Agenebio, Inc. (US) 2016-01-20 EP disclosed
EP-2968257-A1 METHODS AND COMPOSITONS FOR IMPROVING COGNITIVE FUNCTION The Johns Hopkins University (US) 2016-01-20 EP disclosed
EP-2919788-A1 METHODS AND COMPOSITIONS FOR TREATING SCHIZOPHRENIA The Johns Hopkins University (US) 2015-09-23 EP disclosed
WO-2014144663-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION THE JOHNS HOPKINS UNIVERSITY (US) 2014-09-18 WO disclosed
WO-2014144546-A1 METHODS AND COMPOSITONS FOR IMPROVING COGNITIVE FUNCTION THE JOHNS HOPKINS UNIVERSITY (US) 2014-09-18 WO disclosed
WO-2014144801-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION AGENEBIO INC. (US) 2014-09-18 WO disclosed
WO-2014078568-A1 METHODS AND COMPOSITIONS FOR TREATING SCHIZOPHRENIA THE JOHNS HOPKINS UNIVERSITY (US) 2014-05-22 WO disclosed
EP-1912966-A2 2-OXO-1-PYRROLIDINE DERIVATIVES AND THEIR THERAPEUTIC USE ON THE CENTRAL NERVOUS SYSTEM UCB, S.A. (BE) 2008-04-23 EP disclosed
WO-2006128692-A2 2-OXO-1-PYRROLIDINE DERIVATIVES AND THEIR THERAPEUTIC USE ON THE CENTRAL NERVOUS SYSTEM UCB PHARMA, S.A. (BE) 2006-12-07 WO disclosed